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Abstract: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease 
in children and an important cause of short-term and long-term disability. Gene changes in 
the immune system can predispose to JIA and regulation of the immune system is crucial in 
the pathogenesis. The goal of therapy is complete disease control using disease-modifying 
antirheumatic drugs (DMARDS). Activated T-cells may play a role in the immunopathology 
of JIA. Therefore, targeting T-cell activation is a rational approach for the treatment of JIA. 
Abatacept (ABA), a selective co-stimulation modulator, has been shown to be effective in 
treating all JIA subtypes and is generally safe and well tolerated in JIA. Neutralizing antibodies 
were found in 6/9 (67%) of seropositive patients, but anti-ABA antibodies did not appear 
to be associated with disease ﬂ  are, serious adverse events, acute infusional adverse events, 
hypersensitivity, autoimmune disorders, or low ABA serum concentrations. Anti-ABA anti-
bodies were more frequent when ABA concentrations were below therapeutic levels. Although 
information on ABA in JIA is still limited, available data suggest a potential role in difﬁ  cult 
to treat JIA patients previously treated with other biologic agents and for non-responders to 
TNF-blockade.
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Introduction
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease 
in children and an important cause of short- and long-term disability in childhood. 
The incidence of JIA in Europe and North America is estimated to be 10 to 19 cases 
per year for every 100,000 children (Andersson Gare 1999). JIA is not a single 
disease but encompasses all subtypes of idiopathic arthritis in childhood with disease 
onset prior to age 16, and persistence for more than 6 weeks (Ravelli and Martini 
2007). The 2004 International League of Associations for Rheumatalogy (ILAR) 
classiﬁ  cation differentiates 7 distinct JIA subtypes: systemic arthritis, oligoarthritis 
(persistent oligoarthritis, extended polyarticular), polyarthritis rheumatoid factor (RF) 
positive, polyarthritis RF negative, psoriatic arthritis, enthesitis-related arthritis, and 
undifferentiated arthritis (Petty et al 2004) (Table 1).
Treatment of JIA has changed fundamentally over the past 20 years. Less toxic 
and more efﬁ  cacious therapies including methotrexate (MTX) and leﬂ  unomide were 
introduced for the treatment for JIA. Novel technologies and ground-breaking basic 
science research in immunology have identiﬁ  ed key factors involved in inﬂ  ammation 
in JIA. These immune mediators and cell surface receptors are novel targets in children 
with refractory disease.
Pathophysiology of JIA
The etiology of JIA remains poorly understood. Both genetic and environmental 
factors may play a role in the pathogenesis of JIA (Ravelli and Martini 2007). Biologics: Targets & Therapy 2008:2(4) 866
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A single causative gene defect for all JIA subtypes appears 
very unlikely, since the distinct clinical entities are 
minimally overlapping. A genome-wide scan in affected 
families suggested that several genes are associated with the 
development of JIA (Thompson et al 2004).
Susceptibility to JIA, and incidence and disease severity 
were shown to vary among ethnicities. Genetic polymorphisms 
of cytokines and their receptors may predispose for disease 
susceptibility. Distinct single-nuclear polymorphisms (SNPs) 
were found in systemic JIA patients, suggesting a pivotal role 
for mutations in regulatory elements of cytokine genes such as 
IL-6 (Fishman et al 1998; De Benedetti et al 2003).
Adaptive immune system
Both the innate and the adaptive immune system are important 
in the pathogenesis of JIA. Certain HLA-DR patterns are 
associated with particular JIA subtypes, suggesting a central 
role for the adaptive immune system in the etiology of JIA 
(Gattorno et al 2005; Martini et al 2005).
Populations of highly activated, possibly autoreactive 
T-cells can be detected in the synovium of JIA patients, 
suggesting a possible regulatory T-cell defect. Regulatory 
T-cells (Tregs) were shown to prevent the expansion of 
autoreactive T-cells. Children with oligoarticular JIA and long 
symptom-free intervals were found to have higher proportions 
of both synovial and peripheral Tregs (de Kleer et al 2004). 
The intracellular transcription factor FOXP3 is a characteristic 
marker of Tregs. FOXP3 expression is detectable in 40% of 
peripheral T cells in JIA patients. Higher levels of FOXP3 
positive Tregs in the peripheral blood and synovial ﬂ  uid of 
children with oligo JIA were shown to be associated with a 
more favorable disease course (de Kleer et al 2004).
B-cells are also important in JIA, as indicated by positive 
antinuclear antibody titers. In JIA, high B-cell numbers 
were found in the inﬂ  ammatory synovial inﬁ  ltrate (Gregorio 
et al 2007). Faber et al (2006) demonstrated a characteristic 
receptor editing of synovial B-cells.
Innate immune system
Major advances have been made towards understanding 
the actions of the innate immune system in inﬂ  ammation. 
Distinct molecular activation patterns, the pathogen associated 
molecular patterns (PAMPS) and damage associated 
molecular pattern (DAMPS) were recently characterized 
(Fall et al 2007). PAMPS and DAMPS both bind to pattern 
recognition receptors. The activation of the inﬂ  ammatory 
cascade might play an essential role in the pathogenesis 
of JIA. Distinct activation molecular patterns were more 
commonly found in children with systemic JIA (Fall et al 
2007). The inﬂ  ammasome is a protein complex present in 
macrophages and neutrophilic granulocytes. PAMPS and 
DAMPS have been shown to activate the inﬂ  ammasome 
ultimately leading to activation of the pro-inﬂ  ammatory 
cytokine IL-1ß. Mutations of genes coding structures within 
the inﬂ  ammasome are suggested to be a possible cause of 
systemic onset JIA (Woo et al 2005; Yokota et al 2005; 
Lequerre et al 2008). Infections can trigger ﬂ  ares in JIA 
possibly through PAMPS (Massa et al 2002).
Pro-inﬂ  ammatory cytokines play a central role in JIA, 
which is also reﬂ  ected in the efﬁ  cacy and use of biologic 
agents. Tumor necrosis factor (TNF)-α antagonists are used 
in RF negative polyarthritis and blockers of IL-1 and IL-6 
are used in systemic JIA (Woo et al 2005; Yokota et al 2005; 
Lequerre et al 2008).
Table 1 International League of Associations for Rheumatology (ILAR) classiﬁ  cation for Juvenile Idiopathic Arthritis (JIA)
Classiﬁ  cation Characteristics
Systemic arthritis Arthritis in one or more joints, onset with fever, rash, or other systemic symptoms
Oligoarthritis
 Persistent  oligoarthritis
 Extended  polyarticular
Arthritis affecting 1 to 4 joints for the ﬁ  rst months of disease
Polyarthritis
  Rheumatoid factor negative
Arthritis affecting 5 or more joints in the ﬁ  rst 6 months of disease; negative rheumatoid factor
Polyarthritis
  Rheumatoid factor positive
Arthritis affecting 5 or more joints in the ﬁ  rst 6 months of disease; positive rheumatoid factor
Psoriatic arthritis Psoriasis in child or ﬁ  rst degree relative, or dactylitis, nail pitting, oncholysis
Enthesitis-related arthritis HLA-B27 related; formerly called spondylarthropathy
Undifferentiated arthritis Arthritis that fulﬁ  lls criteria in no categories or in 2 or more of the above categories
Derived from Petty 2004.Biologics: Targets & Therapy 2008:2(4) 867
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Treatment of JIA
The treatment of JIA is specifically targeted to each 
JIA subtype. The management of JIA encompasses 
pharmacological interventions, physical and occupational 
therapy, and also psychosocial support (Ilowite 2002; 
Hashkes and Laxer 2005).
The aim of JIA treatment is to achieve disease control, 
preserve the physical and psychological integrity of the child, 
and to prevent any long-term sequelae of disease or therapy.
Prior to 1990, JIA treatment was based on the pyramid 
approach, initially using nonsteroidal anti-inflammatory 
drugs (NSAIDs) and corticosteroids and gradually advancing 
to DMARDS. However, recent studies have indicated that 
previous assumptions on the benign course and outcome of 
JIA were incorrect. Radiological joint damage was thought 
to occur late in the disease course only. In fact, Wallace and 
Levinson reported that most children with systemic arthritis and 
polyarthritis have evidence of radiological joint damage within 
2 years of disease (Wallace and Levinson 1991; Levinson and 
Wallace 1992). In a review on the medical treatment of JIA, 
Hashkes and Laxer (2005) found that most children never 
achieve a long-term remission, and concluded that the burden 
of disease to the patient, family, and society is large.
Subsequently, the JIA treatment paradigms changed: 
health care providers treat JIA patients earlier and consider 
novel, biologic therapy options in order to achieve disease 
control and prevent damage.
Standard therapy in JIA
The pharmacological treatment of JIA includes antiinﬂ  am-
matory and immuno-modulatory medications plus additional 
corticosteroid joint injections. None of these available drugs is 
thought to have curative potential (Hashkes and Laxer 2005).
NSAIDs
NSAIDs are commonly ﬁ  rst-line therapy for JIA patients. 
They are considered a symptomatic treatment option, 
reducing pain, morning stiffness, and fever associated 
with systemic arthritis. Only in a minority of patients with 
oligoarthritis are NSAIDs alone sufﬁ  cient to control the 
disease (Giannini and Cawkwell 1995).
MTX and leﬂ  unomide
Since its introduction in the early 1990s, MTX remains the 
treatment cornerstone for most children with polyarthritis 
(Niehues et al 2005). In systemic JIA, MTX seems to be 
less effective (Niehues et al 2005; Hashkes and Laxer 2006). 
Leﬂ  unomide is the alternative to MTX. It has been shown to 
produce similar response rates in patients with polyarticular 
JIA. Leﬂ  unomide is an option for patients who fail MTX 
or discontinue MTX because of side effects (Silverman 
et al 2005).
Novel biologic therapies
With the introduction of biologics, the treatment options for 
JIA have changed and improved markedly (Hashkes and 
Laxer 2006). Biologics are genetically engineered drugs that 
work by either selectively blocking the effects of cytokines 
or interfering with biological pathways directly and affecting 
immunologic effectors.
Cytokines are important signaling molecules that 
orchestrate host defense. They may act pro- or anti-
inﬂ  ammatory (Wilkinson et al 2003). Currently only the TNF 
blockers etanercept and adalimumab have been approved in 
many countries for the treatment of refractory, polyarticular 
JIA in children age 4 to 17 years. Controlled and uncontrolled 
studies provide consistent evidence on the general efﬁ  cacy 
of etanercept in JIA. TNF blockade also seems to be highly 
effective in enthesitis-related arthritis and polyarthritis but 
less effective in patients with systemic arthritis (Kimura et al 
2005; Hashkes and Laxer 2006).
However, several biologics have also been linked to 
rare but severe adverse events such as lymphoma, serious 
infections, demyelinations, and hepatotoxiticity (Gartlehner 
et al 2006).
Limitation of standard therapy
About 50% of children with JIA do not achieve remission 
despite treatment and require further rheumatological care 
as adults (Minden et al 2000). Treatment-resistant courses 
of JIA result in joint destruction and growth retardation, 
which lead to major functional limitations. Speciﬁ  cally, 
patients with polyarticular onset have the poorest prognosis, 
with a remission rate of only 15% over 10 years (Minden 
et al 2000). Therefore development of new approaches 
and evaluation of new therapeutic options are warranted. 
In addition to blocking the action of cytokines, targeting 
T-cell function is a promising approach. While T-cell 
depletion by anti-CD4 therapy was not effective in JIA 
(Horneff 1995), modulation of T-cell function may have a 
therapeutic impact.
Targeting T -cells in JIA 
as a therapeutic option
There is increasing evidence suggesting that activated T-cells 
may play a fundamental role in the immunopathology of JIA Biologics: Targets & Therapy 2008:2(4) 868
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either by directly inﬂ  uencing other cell types through cell-to-cell 
contact or by producting immunomodulatory cytokines 
(Niehues et al 2008). One of the initial steps in T-cell activation 
is antigen recognition through the T-cell receptor. Following 
antigen recognition, T-cells require co-stimulation to 
become fully activated. One of the best-characterized 
costimulatory pathways is the engagement of  CD 80/CD86 
on antigen-presenting cells (APCs) with CD 28 on T-cells 
(Figure 1a). This produces a positive costimulatory signal 
and promotes full T-cell activation (Smolen and Steiner 
2003). While naive T-cells are classically thought to be more 
dependent on a costimulatory signal than activated T-cells, 
there is evidence that autoimmune effector T-cells also require 
a costimulatory signal for their maintenance (Schweitzer 
and Sharpe 1998; Chang et al 1999). There are several very 
important pathways involved in T-cell activation, some of 
which optimize T-cell activity and some of which cause 
down-regulation. The most important ligand is CTLA-4, a 
well-deﬁ  ned down-regulator of T-cell activation, which has 
a much higher binding afﬁ  nity for CD80/CD86 than CD28. 
Its expression is increased on the T-cell surface 24 to 48 hours 
after T-cell activation. Abatacept (ABA) is a novel biologic 
agent, targeting CD28/B7 interaction (Figure 1).
Focus of review
The focus of this review is to summarize available data on 
ABA targeting T-cells and its potential role in refractory 
JIA. A phase III multicenter, multi-national, randomized 
withdrawal study, which was performed to evaluate the safety 
and efﬁ  cacy of ABA in children and adolescents with active 
juvenile rheumatoid arthritis/JIA (JRA/JIA), will be reviewed 
in detail (Ruperto et al 2008).
Abatacept-history
Abatacept or CTLA-4 Ig is a fully human, soluble 
recombinant fusion protein comprising the extracellular 
domain of human CTLA-4 and a fragment of the 
Fc- domain of human IgG-1, which has been modiﬁ  ed 
to prevent complement ﬁ  xation. ABA competes with the 
high binding avidity of CTLA-4 for CD80/CD86 on APCs 
to competitively bind CD80/CD86. This prevents these 
molecules from engaging CD 28 on T-cells and selectively 
modulates these costimulatory pathways, preventing full 
T-cell activation. ABA shows linear pharmakokinetic 
characteristics, only limited inter-individual variability, 
and has a serum-half-life of 14.7 days (Abrams et al 1999). 
ABA has been tested and has shown efﬁ  cacy in preclinical 
studies involving many animal models of autoimmune 
disease (Finck et al 1994; Webb et al 1996) and allograft 
rejection (Lin et al 1993).
Abatacept in adult rheumatoid 
arthritis (RA)
Efﬁ  cacy and safety of ABA in the treatment of RA were 
ﬁ  rst evaluated using ABA as monotherapy in a dose-ﬁ  nding 
pilot study in patients with active early RA refractory to 
DMARDS (Moreland et al 2002). It led to a dose-dependent 
response as measured by percentages of RA patients 
meeting the American College of Rheumatology (ACR) 
20% improvement criteria. A subsequent phase IIb trial 
compared combination therapy of ABA plus methotrexate 
(MTX) with MTX alone in patients with active RA. 
Combination therapy effectively controlled the signs and 
symptoms of RA and improved patients’ physical function 
and health-related quality of life. Trials in adult RA have 
shown that ABA induces improvement in disease and 
health-related quality of life, and inhibits progression 
of structural damage in patients who did not respond to 
other disease-modifying antirheumatic drugs or anti-TNF 
therapy (Kremer et al 2003, 2006). A 2-year follow up of 
RA patients with difﬁ  cult-to-treat disease showed sustained 
improvement of signs and symptoms of RA, physical 
function, and health-related quality of life after 6 months 
(Genovese et al 2008).
Figure 1 Abatacept modulates T-cell reaction by co-stimulation.
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Weinblatt et al (2006) reported that the combination 
of ABA and etanercept in RA patients was associated 
with an increase in serious adverse events (SAEs) 
with only limited clinical benefit. Subsequently the 
authors advised against the use of ABA in combination 
with etanerecpt for the treatment of RA (Weinblatt 
et al 2007).
Abatacept in JIA
A randomized controlled trial of ABA in JIA (Ruperto 
et al 2008) was a phase III, double-blind, randomized, 
controlled withdrawal trial in children with JIA including 
extended oligoarticular, polyarticular, positive or negative 
for rheumatoid factor, or systemic JIA without systemic 
manifestations. The aim of the study was to assess the 
clinical efﬁ  cacy and safety of abatacept compared with 
placebo in children, who had active JIA and either inadequate 
response, or intolerance to at least one DMARD, including 
some patients who had failed anti-TNF therapy. The study 
included children ages 6 to 17 years, with current active 
arthritis in at least 5 joints, 2 with limitation of motion 
and failure to treatment with at least 1 DMARD including 
biologic therapy. All patients received ABA 10 mg/kg to 
a maximum of 1000 mg (iv infusion) on day 1, 15, and 
every 28 days thereafter in the 4-month open-label (OL) 
lead-in period. MTX was permitted at a dosage of 10 to 
30 mg/m2/week and prednisone at a dose of 0.2 mg/kg/day. 
At the end of the OL lead-in period (day 113), response was 
assessed by ACR pediatric improvement criteria (ACR Pedi) 
30, 50, 70, and 90. All ACR Pedi 30 responders were eligible 
for randomization. Patients were randomized 1:1 to receive 
either ABA 10 mg/kg or placebo for 6 months (Figure 2).
The primary endpoint was time to JIA ﬂ  are deﬁ  ned 
as worsening of 30% or more in at least 3 of the 6 ACR 
core-response variables for JIA, and at least 30% improve-
ment in no more than 1 variable during the double-blind 
period (Brunner et al 2002). Secondary objectives included 
the proportion of patients who had disease ﬂ  are; the changes 
from baseline in each of the 6 ACR core variables; and 
assessment of safety and tolerability.
OL phase
A total of 190 patients with JIA were enrolled (Period A), 
77% were Caucasian; 72% were female; the mean age 
was 12.4 years. Distribution of JIA subtypes: 64% were 
polyarticular JRA/JIA (20% RF positive), systemic JRA/JIA 
in 20%, extended oligoarticular in 14%, and surprisingly 
persistent oligoarticular JRA/JIA in 2%. Limited information 
is provided about the choices and duration of previous 
therapies. A total of 30% were previously treated with 
anti-TNF therapy, which was most commonly discontinued 
for lack of efﬁ  cacy in 27%. Concomitant MTX was given to 
74% of patients (140/190) at a mean dose of 13 mg/m2/week, 
similar in both groups.
Randomized phase
The lead-in period was completed by 170 patients 
(89%), of which 123 were responders (ACR Pedi 30 
improvement) and 122 patients were randomized. Baseline 
demographic and clinical characteristics were similar 
between the treatment group and placebo controls. 
The rates of ACR Pedi 30 responders were similiar across 
the subtypes of JIA: polyarticular–RF positive (26/38, 68%); 
polyarticular–RF negative (54/84, 64 %); systemic (24/37, 
65%); oligoarticular extended (16/27, 59.3%); and persistent 
oligoarticular 2/2.
Outcome
Flare rate
A signiﬁ  cantly higher ﬂ  are rate was observed in placebo-treated 
patients than ABA-treated patients over 6 months. A total of 
33/62 (53%) placebo-treated patients ﬂ  ared and were switched 
to open-label ABA. In contrast, only 12/60 (20%) ABA-treated 
patients ﬂ  ared (p = 0.002, Figure 3). In the ABA group, 
49/60 completed the 6-month randomized phase, whereas 
only 31/62 placebo treated children did. Unfortunately, no 
information is provided about the JIA subtypes that either had 
sustained responses or disease ﬂ  ares.
ACR pediatric 30, 50, 70 responses
In the open label phase, ABA was efﬁ  cacious in patients of 
all JIA subtypes. In the randomized phase the overall ACR 
pediatric 30 response rate was not signiﬁ  cantly different 
Figure 2 Study design of the randomized double-blinded withdrawal trial of abatacept 
versus placebo for children with polyarticular course of juvenile idiopathic arthritis 
(        JIA) Adapted from Giannini et al 2006.
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between ABA and placebo (82% for ABA vs 67% for 
placebo; p = 0.17). The ACR pediatric 50 response rate was 
signiﬁ  cantly different (77% for ABA vs 52% for controls; 
p = 0.007). ACR pediatric 70 rate were also signiﬁ  cantly 
different (53% for ABA vs 31% for controls p = 0.019). 
Within the ACR pediatric core set the number of active joints 
(ABA: 5.4–4.4 at 6 months, placebo 3.9–6.0 at 6 months), the 
number of joints with limited range of motion (ABA 8.0–8.0, 
placebo 7.4–8.6 at months), physician global assessments 
scale, the Child Health Assessment Questionnaire, and 
C-reactive protein showed statistically signiﬁ  cant differences 
between the groups at 6 months. In contrast patient-derived 
measures and erythrocyte sedimentation rate did not 
differ between treatment and control groups (Figure 4). 
The distribution of response among JIA subtypes is not 
reported in the publication.
Safety
Adverse events were reported in 70% of abatacept-treated 
patients during the open-label period and in 62% in the 
double-blind period. Mild infusion reactions were seen in 
4%. During the lead-in period 6 patients had serious adverse 
events; 3 were related to the underlying JIA. The others 
were varicella zoster infections, ovarian cysts, and acute 
lymphocytic leukemia. The safety data are summarized in 
Table 2 (Ruperto et al 2008).
Immunogenicity of abatacept 
(Sigal et al 2007)
ABA-speciﬁ  c antibodies against the entire ABA molecule or 
the CTLA-4 portion were measured by ELISA. Speciﬁ  city 
of antibodies was defined using a competition assay. 
Neutralizing activity was evaluated in a cell-based bioassay. 
Of the 188 patients evaluated in the trial, 40 (21.3%) were 
seropositive at least once, 1.2% (2/162) had ABA-speciﬁ  c 
antibodies, 20.7% (39/188) had anti-CTLA-4-specific 
antibodies, and 1 patient had both. Most patients did not have 
antibodies at 2 or more consecutive visits. Seropositivity did 
not appear to be associated with disease ﬂ  are, SAE, acute 
infusional AE, hypersensitivity, autoimmune disorders, or low 
through ABA serum concentrations. Anti-ABA-antibodies 
were more frequent when ABA concentrations were below 
therapeutic levels. Of seropositive patients evaluated, 
6/9 (67%) had neutralizing antibodies.
Summary of phase III multicenter 
randomized withdrawal study
In this study, treatment with abatacept signiﬁ  cantly reduced 
disease activity in JIA. After the lead-in open label phase, 
65% (123/190) reached an ACR Pedi 30, 47% an ACR 
Pedi 50 (90/190), and 29% (55/190) an ACR Pedi 70. 
A significant difference was noted in responder rates 
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Figure 3 Flare-free survival of patients with juvenile idiopathic arthritis (JIA) treated with either abatacept or placebo. The graph demonstrates the proportion of patients 
without disease ﬂ  are during the 6-month double-blind period. P value represents the comparison of the time to disease ﬂ  are between the abatacept and placebo groups. 
Adapted from The Lancet, 372, Ruperto N, Lovell DJ, Quartier P, et al; Paediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study 
Group. 2008.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial, 383–91, Copyright © 2008 with permis-
sion from Elsevier.Biologics: Targets & Therapy 2008:2(4) 871
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between patients previously treated with biologic therapies 
and biologics-naive JIA patients. Responder-rates of 
biologics-naive JIA patients were twice as high as those seen 
in pre-treated JIA patients.
The enrichment design of the trial then only included ACR 
Pedi 30 responders into the randomized phase. At the end of 
the double-blinded randomized phase (day 169) the ACR 
pediatric 50 responder rate increased from 67% to 77% in the 
ABA group, while the rate decreased from 87% to 52% in the 
controls. Similarly the rate of ACR Pedi 70 responders further 
increased in the ABA group from 38% to 53%, while it dropped 
from 50% to 31% in controls (Figure 4) (Ruperto et al 2008).
ABA was generally safe and well tolerated. The overall 
incidence of AE was similar in the ABA and placebo groups. 
No discontinuation of therapy because of adverse events 
was noted. Antibodies to ABA were more frequently seen 
in patients with protocol-deﬁ  ned therapy interruption than in 
patients on continuous therapy. The transient seropositivity 
did not appear to be associated with decreased clinical 
efﬁ  cacy. ABA-speciﬁ  c antibodies appeared to be of no 
clinical signiﬁ  cance.
Conclusions
JIA is a common, chronic illness of childhood associated 
with major long-term disability. Basic science research 
advances have provided insights into the pathogenesis of JIA, 
identifying key factors and crucial mechanisms that perpetuate 
inflammation. T-cells play a pivotal role predominantly 
Figure 4 Efﬁ  cacy of abatacept: Rate of responders during the double-blinded withdrawal of abatacept versus placebo in patients with juvenile idiopathic arthritis (JIA). 
Adapted from The Lancet, 372, Ruperto N, Lovell DJ, Quartier P, et al; Paediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative 
Study Group. 2008.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial, 383–91, Copyright © 2008 with 
permission from Elsevier.
Abatacept group  Placebo group  P value 
Core-response variable  Day 113  Day 282  Day 113  Day 282 
Number of active joints  5.4 (5.5)  4.4 (7.0)  3.9 (5.9)  6.0 (5.8)  0.0245 
Number of joints with 
limited range of motion  8.8 (10.7)  8.8 (12.8)  7.4 (12.6)  8.6 (12.0)  0.0128 
Physician´s global 
assessment  15.9 (12.5)  14.7 (18.9)  12.5 (12.5)  23.2 (12.8)  0.0004 
CHAQ disability index  0.8 (0.8)  0.8 (0.9)  0.7 (0.6)  0.8 (0.7)  0.0388 
Erythrocyte sedimentation 
rate (mm/h)   22.2 (20.8)  25.1 (26.4)  23.1 (25.0)  30.7 (30.1)  0.9562 
C-reactive protein  0.17 (0.24)  0.16 (0.25)  0.18 (0.33)  0.29 (0.54)  0.0255 
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mediated through cell–cell interactions facilitated through 
co-stimulatory molecules such as CTLA-4 and its ligands.
Therapy of JIA has advanced substantially. With the 
introduction of MTX and leﬂ  unomide, two highly effective 
and less toxic DMARDS became available. TNF-alpha 
inhibitors increased the rate of children achieving disease 
control and remission on medication. Nevertheless, 
some patients do not respond to existing agents or may 
not be candidates for them, while others are unable to 
tolerate them.
Abatacept is the ﬁ  rst of a novel class of therapies, the 
selective co-stimulation modulators. In the single pediatric 
trial available, ABA led to a 65% ACR Pedi 30 response 
rate despite including a highly selected population of severe 
polyarticular arthrits patients in the study. Children enrolled 
in the trial had previously failed TNF blockage and had 
ongoing disease activity despite concomitant DMARD 
therapy. These results suggest that abatacept could also be 
effective in patients who have failed previous treatment 
with anti-TNF agents. The safety proﬁ  le was favorable. 
ABA may play an important role in the future treatment of 
children with refractory JIA primarily. Long-term studies are 
needed to assess sustained efﬁ  cacy and safety of this novel 
therapy for JIA.
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Abbreviations
ABA, abatacept; ACR, American College of Rheumatology; 
APC, antigen presenting cell; DAMP, damage associated 
molecular pattern; DB, double blind; DMARDS, disease 
Table 2 Adverse events in juvenile idiopathic arthritis (        JIA) patients treated with either abatacept or placebo
4-month open-label 
period
6-month double-blind period
Abatacept (N = 190) Abatacept (N = 60) Placcbo (N = 62) p value*
Total serious adverse events   6 (3%)   0   2 (3%) 0.50
Total adverse events† 133 (70%) 37 (62%) 34 (55%) 0.47
Infections and infestations 68 (36%) 27 (45%) 27 (44%) 1.00
 Inﬂ   uenza  7  (4%)  5  (8%)  4  (7%) 0.74
  Bacteriuria  3  (2%)  4  (7%)  0 0.06
  Nasopharyngitis 11 (6%)   4 (7%)   3 (5%) 0.72
  Upper respiratory tract infection 14 (7%)   4 (7%)  5  (8%) 1.00
  Gastroenteritis  1  (0.5%)  3  (5%)  1  (2%) 0.36
  Sinusitis  6  (3%)  3  (5%)  2  (3%) 0.68
  Rhinitis  8  (4%)  1  (2%)  4  (7%) 0.36
Gastrointestinal disorders 66 (35%) 10 (14%)   9 (15%) 0.81
  Abdominal pain   9 (5%)   3 (5%)   1 (2%) 0.36
  Nausea 19 (10%)   2 (3%)   4 (7%) 0.68
  Diarrhea 17 (9%)   1 (2%)   1 (2%) 1.00
  Upper abdominal pain 10 (5%)   1 (2%)   0 0.49
General disorders 
and administration site conditions
26 (14%)   4 (7%)   9 (15%) 0.24
  Pyrexia 12 (6%)   4 (7%)   5 (8%) 1.00
Nervous system disorders 30 (16%)   3 (5%)   2 (3%) 0.68
  Headache 25 (13%)   3 (5%)   1 (2%) 0.36
Respiratory, thoracic 
and mediastinal disorders
32 (17%)   6 (10%)   3 (5%) 0.50
  Cough 17  (9%)  0  2  (3%) 0.50
*Fisher’s test used to test the difference between groups given abatacept and placebo in the double-blind phase.
†Adverse events that occurred in at least 5% of patients in the open-label and double-blind phases.
Adapted from The Lancet, 372, Ruperto N, Lovell DJ, Quartier P, et al; Paediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study 
Group. 2008.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial, 383–91, Copyright © 2008 with permis-
sion from Elsevier.Biologics: Targets & Therapy 2008:2(4) 873
Abatacept in JIA
modifying antirheumatic drugs; HLA, human leukocyte 
antigen; IL, interleukin; ILAR, International League of 
Associations for Rheumatology; JIA, juvenile idiopathic 
arthritis; MHC, major histocompatibility complex; MTX, 
methotrexate; NLR, NOD proteins containing leucine-rich 
repeats; NOD, nucleotide oligomerisation domain; NSAID, 
nonsteroidal anti-inflammatory drugs; OL, open label; 
PAMP, pathogen associated molecular pattern; PRR, pattern 
recognition receptor; RA, rheumatoid arthritis; RAGE, 
receptor for advanced glycation endproducts; RF, rheumatoid 
factor; SAE, serious adverse event; SNPs, single-nuclear 
polymorphisms; TLR, toll-like receptors; TNF, tumor 
necrosis factor; Tregs, regulatory T-cells.
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